These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 4140382

  • 1. Letter: Lithium and M.R.I.H. in tardive dyskinesia.
    Ehrensing RH.
    Lancet; 1974 Dec 14; 2(7894):1459-60. PubMed ID: 4140382
    [No Abstract] [Full Text] [Related]

  • 2. Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study.
    Ehrensing RH, Kastin AJ.
    Arch Gen Psychiatry; 1974 Jan 14; 30(1):63-5. PubMed ID: 4587068
    [No Abstract] [Full Text] [Related]

  • 3. Letter: Lithium and haloperidol in movement disorders.
    McCaul JA, Stern GM.
    Lancet; 1974 May 25; 1(7865):1058. PubMed ID: 4133743
    [No Abstract] [Full Text] [Related]

  • 4. Management of tardive dyskinesia with thiopropazate.
    Curran JP.
    Am J Psychiatry; 1973 Aug 25; 130(8):925-7. PubMed ID: 4146097
    [No Abstract] [Full Text] [Related]

  • 5. Tardive dyskinesia: side effect or not?
    Curran JP.
    Am J Psychiatry; 1973 Apr 25; 130(4):406-10. PubMed ID: 4144163
    [No Abstract] [Full Text] [Related]

  • 6. Letter: Lithium in Parkinson's disease.
    McCaul JA, Stern GM.
    Lancet; 1974 Jun 01; 1(7866):1117. PubMed ID: 4135282
    [No Abstract] [Full Text] [Related]

  • 7. Letter: Treatment of tardive dyskinesia with lithium carbonate.
    Reda FA, Scanlan JM, Kemp K, Escobar JI.
    N Engl J Med; 1974 Oct 17; 291(16):850. PubMed ID: 4420111
    [No Abstract] [Full Text] [Related]

  • 8. Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom.
    Fischer PA, Schneider E, Jacobi P, Maxion H.
    Eur Neurol; 1974 Oct 17; 12(5-6):360-8. PubMed ID: 4614981
    [No Abstract] [Full Text] [Related]

  • 9. Lithium carbonate in the treatment of tardive dyskinesia.
    Reda FA, Escobar JI, Scanlan JM.
    Am J Psychiatry; 1975 May 17; 132(5):560-2. PubMed ID: 804260
    [Abstract] [Full Text] [Related]

  • 10. Hypothalamic releasing factors and Parkinson disease.
    Chase TN, Woods AC, Lipton MA, Morris CE.
    Arch Neurol; 1974 Jul 17; 31(1):55-6. PubMed ID: 4209275
    [No Abstract] [Full Text] [Related]

  • 11. Production of MSH-release-inhibiting hormone by a particulate preparation of hypothalami: mechanisms of oxytocin inactivation.
    Walter R, Griffiths EC, Hooper KC.
    Brain Res; 1973 Oct 12; 60(2):449-57. PubMed ID: 4587290
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of tardive dyskinesia.
    Widroe HJ, Heisler S.
    Dis Nerv Syst; 1976 Mar 12; 37(3):162-4. PubMed ID: 3393
    [Abstract] [Full Text] [Related]

  • 13. Behavioral effects of thyrotropin releasing hormone in animals and man: a generic hypothesis.
    Prange AJ, Wilson IC.
    Psychopharmacol Bull; 1975 Jan 12; 11(1):22-4. PubMed ID: 804704
    [No Abstract] [Full Text] [Related]

  • 14. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial.
    Gerlach J, Thorsen K, Munkvad I.
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Mar 12; 8(2):51-6. PubMed ID: 788002
    [Abstract] [Full Text] [Related]

  • 15. Estrogen influence on the hypothalamic enzymes involved in the formation of melanocyte-stimulating hormone release-inhibiting factor (MSH-R-IF).
    Celis ME, Taleisnik S.
    Proc Soc Exp Biol Med; 1974 Jan 12; 145(1):142-4. PubMed ID: 4591390
    [No Abstract] [Full Text] [Related]

  • 16. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides.
    Castensson S, Sievertsson H, Lindeke B, Sum CY.
    FEBS Lett; 1974 Aug 15; 44(1):101-5. PubMed ID: 4212370
    [No Abstract] [Full Text] [Related]

  • 17. Site of inactivation of melanocyte-stimulating hormone-release-inhibiting hormone by human plasma.
    Nair RM, Redding TW, Kastin AJ, Schally AV.
    Biochem Pharmacol; 1973 Aug 01; 22(15):1915-9. PubMed ID: 4578947
    [No Abstract] [Full Text] [Related]

  • 18. Lithium carbonate, haloperidol, and irreversible brain damage.
    Cohen WJ, Cohen NH.
    JAMA; 1974 Dec 02; 230(9):1283-7. PubMed ID: 4479505
    [No Abstract] [Full Text] [Related]

  • 19. Letter: Clomipramine infusion and lithium carbonate: a synergistic effect?
    O'Flanagan PM.
    Lancet; 1973 Oct 27; 2(7835):974. PubMed ID: 4126603
    [No Abstract] [Full Text] [Related]

  • 20. Lithium carbonate for depression and mania.
    Wharton RN.
    JAMA; 1970 Feb 23; 211(8):1379. PubMed ID: 5467042
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.